On November 2, 2021 Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, reported that scientific posters sharing preclinical data will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2021 Annual Meeting, to be held virtually and at the Walter E. Washington Convention Center in Washington, D.C. November 10-14, 2021 (Press release, Surface Oncology, NOV 2, 2021, View Source [SID1234594128]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The posters include preclinical data from Surface Oncology’s two lead clinical-stage antibody therapies: SRF617 (targeting CD39) and SRF388 (targeting IL-27), both of which are in Phase 1 clinical studies. Surface scientists will be in attendance on-site in Washington D.C. to present the data. Full posters will be placed on Surface Oncology’s website following the presentations. Details are provided below; full posters will be placed on Surface Oncology’s website following the presentations.

Details of Surface’s SITC (Free SITC Whitepaper) presentations:

Presentation Type: Poster Presentation (Abstract: 247)
Title: The fully human antibody SRF617 is a potent inhibitor of ecto-enzyme CD39 in vivo
Session: Poster Hall Session
Lead Author: Stephan Matissek, Ph.D. and Ricard Masia, M.D., Ph.D.
Presentation Date and Time: November 12, 2021 from 7:00 a.m. to 8:30 p.m.

Presentation Type: Poster Presentation (Abstract: 674)
Title: IL-27 signaling drives a type 1 interferon-like gene expression program of immunoregulatory pathways associated with cancer progression
Session: Poster Hall Session
Lead Author: Devapregasan Moodley, M.D.
Presentation Date and Time: November 13, 2021 from 7:00 a.m. to 8:30 p.m.

About SRF617:
SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39 in the tumor microenvironment, allowing for a dual mechanism of action to promote anti-tumor immunity via reduction of immunosuppressive adenosine in addition to increasing levels of immunostimulatory ATP. A substantial body of research supports a role for CD39 in allowing cancer to evade immune responses. For example, pancreatic cancer stromal cells within the tumor micro-environment express high levels of CD39 which may inhibit anti-cancer immune responses. In preclinical studies, SRF617 has exhibited strong affinity for and inhibition of CD39, the ability to reduce adenosine and increase ATP levels and anti-tumor activity both as a single agent and in combination with multiple therapeutic agents. SRF617 has been granted Orphan Drug designation for the treatment of advanced pancreatic cancer by the FDA.

About SRF388:
SRF388 is a fully human anti-IL-27 antibody designed to inhibit the activity of this immunosuppressive cytokine. Surface Oncology has identified particular tumor types, including liver, kidney and lung cancer, where IL-27 appears to play an important role in the immunosuppressive tumor microenvironment and may contribute to resistance to treatment with checkpoint inhibitors. SRF388 targets the rate-limiting p28 subunit of IL-27, and preclinical studies have shown that treatment with SRF388 blocks the immuno-suppressive biologic effects of IL-27, resulting in immune cell activation in combination with other cancer therapies including anti-PD-1 therapy, as well as potent anti-tumor effects as a monotherapy. Furthermore, Surface Oncology has identified a potential biomarker associated with IL-27 that may be useful in helping to identify patients most likely to respond to SRF388. In November 2020, Surface announced that SRF388 was granted Orphan Drug designation and Fast Track designation for the treatment of hepatocellular carcinoma from the FDA.